Apeloa Pharmaceutical (000739.SZ): The addition of a new 25mg specification for Metoprolol Succinate Extended-Release Tablets has been approved by the US FDA.

Apeloa Pharmaceutical (000739.SZ) announced that its wholly-owned subsidiary Zhejiang Jutai Pharmaceutical Co., Ltd. recently received approval notification from the U.S. Food and Drug Administration (FDA) for the 25mg specification of the Amber Metoprolol Succinate Extended-Release Tablets (ANDA number: 214110) Prior Approval Supplement (PAS). Metoprolol is the world's first selective 1 receptor blocker, which can reduce the risk of bronchoconstriction, making it a commonly used drug for chronic heart failure. The Amber Metoprolol Succinate Extended-Release Tablets are used for the treatment of hypertension, angina pectoris, stable chronic heart failure with symptoms of left ventricular systolic dysfunction, among other indications. The approval of the 25mg specification of the Amber Metoprolol Succinate Extended-Release Tablets will provide more options for market promotion of this product and will help expand the overseas market, thus having a positive impact on the company's business development. The company will further enhance the global market competitiveness of this product and actively explore the U.S. and other overseas markets.